BioVaxys Technology (TSE:BIOV) has released an update.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
BioVaxys Technology Corp has secured a 48-kilogram supply of GMP-grade lipids to advance the production of its DPX-based vaccines, anticipating a significant ramp-up in preclinical and clinical programs. This acquisition is expected to save the company over a year in manufacturing lead time. BioVaxys continues to innovate with its patented DPX platform, aiming to deliver robust immune responses for various medical applications.
For further insights into TSE:BIOV stock, check out TipRanks’ Stock Analysis page.
Trending Articles
- Goldman Sachs Ups Price Target on Super Micro Computer despite Nasdaq Ouster
- Microsoft Leads AI Race with Massive Nvidia GPU Purchases in 2024
- Nike Q2 Earnings Preview: Analysts Expect a Decline in Earnings and Sales
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
